Tubulin-IN-55
Tubulin-IN-55 is a tubulin inhibitor. Tubulin-IN-55 disrupts the PI3K/Akt signaling pathway in cancer cells. Tubulin-IN-55 exerts broad-spectrum anti-proliferative activity against multiple tumor cells (HeLa, HCT116, 4T1, A549, H1299, MDA-MB231). Tubulin-IN-55 induces G2/M phase arrest and apoptosis, and inhibits tumor cell migration/invasion in cancer cells. Tubulin-IN-55 demonstrates potent antitumor efficacy in orthotopic autologous transplantation mice. Tubulin-IN-55 can be used for the study of cancer.
For research use only. We do not sell to patients.
- CAS No.: 353258-94-3
- Formula: C21H26N4O
- Molecular Weight:350.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Tubulin-IN-55 (Compound 89) (0.1-10 μM, 24 h) shows potent antiproliferative activity against HeLa, HCT116, and 4T1 cells, with IC50 values of 1.20 μM, 4.91 μM, 1.13 μM, and 0.65 μM , respectively[1].
Tubulin-IN-55 (0.3-0.9 μM, 12-24 h) exhibits anti-migratory and anti-invasive effects on HeLa, HCT116, and 4T1 cells[1].
Tubulin-IN-55 (0.3-1.2 μM, 24 h) induces apoptosis and G2/M phase arrest in HeLa, HCT116, and 4T1 cells[1].
Tubulin-IN-55 (6.25-100 μM, 60 min) inhibits tubulin polymerization in vitro in a dose-dependent manner[1].
Tubulin-IN-55 (0.3-0.9 μM, 24 h) downregulates the phosphorylation levels of PI3K and Akt in HeLa, HCT116, and 4T1 cells without changing total PI3K and Akt levels[1].
Tubulin-IN-55 (0.1-10 μM, 24 h) exerts antitumor activity on BC-PDO1, BC-PDO2, and BC-PDO10 (breast cancer organoids), reducing organoid viability with IC50 values of 1.07 μM, 0.81 μM, and 0.42 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa, HCT116, and 4T1 cells
-
Concentration:0.3, 0.9 μM
-
Incubation Time:12, 24 h
-
Result:Exhibited anti-migratory effects on HeLa, HCT116, and 4T1 cells.
Upregulated epithelial marker E-Cadherin.
-
Cell Line:HeLa, HCT116, and 4T1 cells
-
Concentration:0.3, 0.9 μM
-
Incubation Time:12, 24 h
-
Result:Exhibited anti-migratory effects on HeLa, HCT116, and 4T1 cells.
Upregulated epithelial marker E-Cadherin.
-
Cell Line:0.3, 0.6, 1.2 μM
-
Concentration:0.3, 0.9 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis.
Increased the proportion of apoptotic cells.
Upregulated cleaved-PARP and Bax, and downregulated Bcl-2.
-
Cell Line:0.3, 0.6, 1.2 μM
-
Concentration:0.3, 0.9 μM
-
Incubation Time:24 h
-
Result:Induced G2/M phase arrest.
Upregulated Cyclin B1 and downregulated CDK1 and Cdc25c.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Tumor cells were implanted into 6-8-week-old BALB/c mice to establish the in vivo tumor model[1]
-
Dosage:10 mg/kg
-
Administration:i.p., once every two days, 4 weeks
-
Result:Achieved tumor growth inhibition.
Suppressed breast cancer metastasis to the lung.
Reduced the Ki67 expression and PCNA expression in tumor tissues.
Disrupted the microtubule network in tumor tissues.
Showed no significant changes in body weight and major organ (heart, liver, spleen, lung, kidney) weights.
Chemical Information
-
CAS No. 353258-94-3
-
Molecular Weight 350.46
-
Formula C21H26N4O
-
SMILES
O=C(N1CCN(CC1)C2=CC=CC=C2)C3=CC=CN=C3N4CCCCC4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz